Trial Profile
An exploratory phase II, multicenter, open-label trial evaluating the activity and tolerability of FK228 in androgen independent metastatic prostate cancer patients with rising PSA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Celgene Corporation; Gloucester Pharmaceuticals
- 08 Nov 2006 Status change
- 01 Oct 2005 New trial record.